Background Logomix is a pioneering synthetic biology company, reshaping the landscape of human genome engineering. With unrivaled expertise in large-scale genome engineering, Logomix drives groundbreaking advancements in the development of multi-functionalized human cells. Our revolutionary Genome-Writing™ platform empowers scientists to introduce precise and extensive genetic alterations, targeting specific loci spanning megabases.

Methods Geno-Writing™ platform represents a groundbreaking leap in genome-writing, enabling precise and extensive alteration within the genomic landscape of human cells. At Logomix, we harness this cutting-edge technology to pioneer the development of human iPSC-derived multifunctional immune cells, effectively bridging the gaps observed in contemporary cell therapy approaches.

Results Our premier accomplishment is the development of universal donor iPSC lines for allogeneic therapy, which feature Mb-scale deletions of both HLA class I and II gene loci, seamlessly integrated with HLA genes of strategic choice. Such refinement result in cells adept at evading immune systems. On top of the hypoimmune technology, our expertise in designing and synthesizing gene clusters of up to 50 kb, which can simultaneously accommodate multiple transgenes, has given rise to versatile iPSC libraries for a multiplexed screening.

Conclusions Each iPSC variant within the libraries embodies distinct gene combinations, which is either established or hypothesized to bolster immune cell evasion. In this presentation, we will unveil compelling evidence underscoring the genomic integrity and functional capabilities of our engineered iPSCs and the screening cell libraries, which solidifies the Geno-Writing™ platform’s position as a cornerstone in driving the future of allogeneic cell therapy and regenerative medicine.